Clayton English

Education:

• Bachelor of Science in Pharmacy Studies-University of Connecticut
• Doctor of Pharmacy-University of Connecticut

Research and Clinical Interests:

• Psychiatric Pharmacy
• Clinical Psychopharmacology
• Drug-Induced Disease
• Deprescribing
• Mood Disorders
• Adult ADHD
• Psychostimulant Use
• Interprofessional Education

Biography

Dr. Clayton English is an Assistant Professor of Pharmacy at the University of Washington School of Pharmacy. Clayton earned his Bachelor of Science and Doctor of Pharmacy degrees from the University of Connecticut in Storrs, Connecticut and subsequently completed a specialty residency in psychiatric pharmacy practice and clinical psychopharmacology at Nova Southeastern University College of Pharmacy in Fort Lauderdale, Florida. He holds board certifications in Psychiatric Pharmacy (BCPP), Pharmacotherapy (BCPS), and Geriatric Pharmacy (BCGP). From 2010 to 2022, Clayton served as a faculty member at Albany College of Pharmacy and Health Sciences (ACPHS) and practiced as a clinical pharmacy specialist in psychiatry at the University of Vermont Medical Center (UVMMC) in Burlington, Vermont. During his time in Vermont, Clayton helped expand clinical pharmacy services within inpatient psychiatry at UVMMC and precepted and assisted in the training of numerous students and residents in both pharmacy and psychiatry. Additionally, Clayton was highly involved in the didactic instruction of neuropsychiatric therapeutics and psychopharmacology across the pharmacy school curriculum.

Clayton has broad clinical and research interests in neurologic and psychiatric pharmacy including safe and appropriate use of psychiatric medications, psychotropic deprescribing, pharmacovigilance, mood disorders, adult ADHD, and drug-induced behavioral disorders. Additionally, Clayton is passionate about interprofessional education, team-based care, and student and resident well-being.

Clayton remains highly engaged in the professional development of pharmacists and enjoys participating in activities and organizations that advocate for the profession. Clayton is an active member of the American Association of Psychiatric Pharmacists (AAPP) and serves as a Senior Editor for the AAPP Psychiatric Pharmacotherapy Review Book and Course. He has been honored for his contributions to the profession and education of students and residents. He was the recipient of the Award of Excellence in Academic Teaching from the University of Vermont Psychiatry Residency Program in 2012, 2017, and 2019 and was recognized in 2013 as the Vermont Pharmacist of the Year by the Vermont Society of Health-Systems Pharmacists. Additionally, he was recognized as the ACPHS Preceptor of the Year in 2015 and Teacher of the Year of the ACPHS Vermont Campus in 2017 and 2021. Outside the classroom, Clayton enjoys exercising, road trips, spending time with his family, and exploring the greater Seattle area for the best coffee around.

Selected Publications

English C, Bode L. Major Depressive Disorder. In: Pharmacotherapy Self-Assessment Program, 2022 Book 3. Behavioral Health. Lenexa, KS: American College of Clinical Pharmacy, 2022.

English C. Depression. In: 2020-2021 Psychiatric Pharmacotherapy Review Course. College of Psychiatric & Neurologic Pharmacists. Lincoln: CPNP; 2020.

English C, Goodwin H, Dickinson JA, Rey JA. Brexanolone: A novel treatment option for postpartum depression. P&T. 2019;44(11):732-736.

Runyan S, Gething M, English C, Rabinowitz T. Pharmacotherapeutics. In: Fundamentals of Consultation Liaison Psychiatry: Neuropsychiatry. 1^st ed. Nova Science Pub Inc; 2019.

DiSciullo AA, English CD, Horn WT. Modafinil Induced Psychosis in a Patient with Bipolar 1 Depression. Case Reports in Psychiatry. 2018;2018:3.

English CD. New therapeutic options for the management of ADHD. US Pharm. 2018;43(5):1-10.

Boyd JT, English C, Lounsbury KM. Antiparkinson Drugs. In: Dowd FJ, Johnson BS, Mariotti AJ. Pharmacology and Therapeutics for Dentistry. 7^th ed. St. Louis: Elsevier; 2017.

English C, Aloi JJ. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
Clin Ther. 2015;37(4):691-715.

Harrington CA, English C, Schaefer S. Systematic review of the post-marketing surveillance of paliperidone. Journal of Symptoms and Signs. 2014;3(1):39-49.

English C, Rey JA, Schlesselman LS. Prevalence of hazardous alcohol use among pharmacy students at nine U.S. schools of pharmacy. Pharmacy Practice (Internet) 2011 Jul-Sep;9(3):162-168.

Harrington CA, English C. Adverse drug events related to ziprasidone: a meta-analysis of randomized, placebo-controlled trials. Pharmacotherapy 2011;31(9):840-849.